The Latest Breaking News from VKTX

Viking Therapeutics stock jumped on rumors of a potential acquirer looking to add a GLP-1 treatment to their portfolio and VK2735 appears to rival Zepbound.

With the growing demand for cutting-edge therapies reshaping the healthcare landscape, here are two “Strong Buy”-rated biotech stocks with significant potential upside.

Rising costs, regulatory hurdles, and cyberattacks are some of the challenges that the pharmaceutical industry faces. Although the sector looks well-positioned for growth, not all pharma stocks would be able to capitalize on the industry trends. Therefore, investors should look to avoid fundamentally weak pharma stocks: Madrigal Pharmaceuticals (MDGL), Viking…

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing drugs to combat obesity. Is TERN stock a good buy right now?

Shares of Viking Therapeutics have been on an absolute tear in 2024, as the biotech stock gears up to enter the weight-loss drug market.

Viking Therapeutics (NASDAQ:VKTX) is set to give its latest quarterly earnings report on Wednesday, 2022-04-27. Here's what investors need to know before the announcement. Analysts estimate that Viking Therapeutics will report an earnings per share (EPS) of $-0.19.

Viking Therapeutics (NASDAQ:VKTX) reported its Q4 earnings results on Wednesday, February 9, 2022 at 04:00 PM. Here's what investors need to know about the announcement.